ReviewRheumatology international2017
Updates on cardiovascular comorbidities associated with psoriatic diseases: epidemiology and mechanisms.
Review in Rheumatology international, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 50 citations in OpenAlex.
- Trial
- Deciphering the Underlying Mechanisms Linking Psoriasis and IgA Nephropathy.Journal of immunology research · 2026Review
- Effectiveness and safety of acupoint catgut embedding for patients with mild psoriasis and overweight: study protocol of a multicenter double-blind randomized controlled trial.Frontiers in medicine · 2026Article
- Article
- Residual Traditional Risk in Non-Traditional Atherosclerotic Diseases.International journal of molecular sciences · 2025Review
- Association between red blood cell distribution width and psoriasis among the US adults.Frontiers in medicine · 2023Article
- The association between psoriatic arthritis and venous thromboembolism: a population-based cohort study.Arthritis research & therapy · 2022Article
- Endothelial Dysfunction in Psoriasis: An Updated Review.Frontiers in medicine · 2022Review
- Related Risk Factors and Treatment Management of Psoriatic Arthritis Complicated With Cardiovascular Disease.Frontiers in cardiovascular medicine · 2022Review
- Psoriasis as risk factor for non-ischemic dilated cardiomyopathy: a population-based cross-sectional study.BMC cardiovascular disorders · 2021Article
- Comorbidities in rheumatic diseases need special consideration during the COVID-19 pandemic.Rheumatology international · 2021Review
- Extra-Articular Manifestations and Comorbidities in Psoriatic Disease: A Journey Into the Immunologic Crosstalk.Frontiers in medicine · 2021Review
- Pathogenesis of psoriasis in the "omic" era. Part III. Metabolic disorders, metabolomics, nutrigenomics in psoriasis.Postepy dermatologii i alergologii · 2020Review
- Pathogenesis of psoriasis in the "omic" era. Part I. Epidemiology, clinical manifestation, immunological and neuroendocrine disturbances.Postepy dermatologii i alergologii · 2020Review
- Cardiac and cardiovascular morbidities in patients with psoriatic arthritis: a population-based case control study.Clinical rheumatology · 2019Article
- Hypertension is associated with increased age at the onset of psoriasis and a higher body mass index in psoriatic disease.Clinical rheumatology · 2019Observational
- Concordance between the Different Cardiovascular Risk Scores in People with Rheumatoid Arthritis and Psoriasis Arthritis.Cardiology research and practice · 2019Article
- Prevalence and type II diabetes-associated factors in psoriatic arthritis.Clinical rheumatology · 2018Article
- Protection from Psoriasis-Related Thrombosis after Inhibition of IL-23 or IL-17A.The Journal of investigative dermatology · 2018Article
- Hypertension as a cardiovascular risk factor in autoimmune rheumatic diseases.Nature reviews. Cardiology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis and psoriatic arthritis are associated with a significantly increased risk of cardiovascular risk factors and major adverse cardiovascular events (MACE). Active research is ongoing to elucidate this relationship between psoriatic diseases and cardiovascular comorbidities, as well as their shared pathogenic mechanisms. This review focuses on (1) the epidemiologic association between psoriasis and cardiovascular risk factors, (2) the epidemiologic association between psoriasis and MACE, (3) the epidemiologic association between psoriatic arthritis, cardiovascular risk factors, and MACE, and (4) proposed mechanisms for the contribution of psoriatic diseases to cardiovascular diseases. The proposed mechanisms for shared pathogenesis between psoriatic diseases and cardiovascular diseases are inflammation, insulin resistance, dyslipidemia, angiogenesis, oxidative stress, and endothelial dysfunction. There is complex interplay and overlap among these mechanisms and their contributions to shared pathogenesis. Future translational research is necessary to elucidate the link between psoriatic diseases and cardiovascular diseases. Such findings may be applied clinically to improve the lives of psoriasis patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.